Senior Vice President, Quality Operations
Danny Tuck joined INSYS Therapeutics in November 2015.
Dr. Tuck has more than 35 years of experience with leading chemical and pharmaceutical companies working primarily in the areas of quality, compliance, quality control, analytical research and product stability. He has demonstrated accomplishments in building commercial and R&D quality organizations and implementing compliance and quality improvements.
As VP of Quality Operations at Elan, Dr. Tuck drove the compliance remediation activities and development of new quality systems leading the site out of an FDA consent decree. At Abraxis Bioscience, Dr. Tuck was responsible for establishing the company’s Quality philosophy, policies, practices, procedures, standards and process systems by which company operations are performed; he also led the development and implementation of the global quality systems to support U.S., E.U. and Japan compliance requirements. At Morton Grove Pharmaceuticals (a division of Wockhardt), Dr. Tuck was responsible for leading and directing the overall activities of U.S. Quality Operations. As VP of Global Quality Compliance at Mylan, he developed a new department responsible for global compliance and all-time inspection readiness; he also led the development and implementation of standardized compliance processes within Mylan Global Quality to assure adherence to quality system regulations at all sites.
At INSYS, Dr. Tuck assures that all activities associated with development, non-clinical and clinical research, manufacturing, testing and distribution of products within the portfolio of the pharmaceutical products manufactured and marketed by the company are in compliance with regulatory requirements. He organizes and promotes company-wide quality and compliance improvement efforts including the development and implementation of corporate quality policies.